Edition:
United Kingdom

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

5.02USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
356,561
52-wk High
$9.25
52-wk Low
$3.95

Latest Key Developments (Source: Significant Developments)

BioCryst Pharma files for mixed shelf of up to $200 million‍​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - BioCryst Pharmaceuticals Inc :Files for mixed shelf of up to $200 million - SEC filing‍​.  Full Article

BioCryst Pharmaceuticals reports Q3 loss per share of $0.18
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - BioCryst Pharmaceuticals Inc ::Reports third quarter 2017 financial results.Q3 loss per share $0.18.Q3 revenue $8.8 million versus $7.8 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.6 million -- Thomson Reuters I/B/E/S.Expect to start single required phase 3 efficacy and long-term safety trials for BCX7353 in Q1 2018 ​.‍U.S. Orphan Drug Designation for BCX7353 received from FDA​.  Full Article

Biocryst Pharmaceuticals prices public offering of common stock
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - Biocryst Pharmaceuticals Inc :Biocryst Pharmaceuticals prices public offering of common stock.Pricing of underwritten public offering of 15.5 million shares of common stock, offered at a price to public of $5.15 per share.  Full Article

D. E. Shaw & Co L.P. reports passive stake of 5.1 pct in Biocryst Pharmaceuticals as of Aug. 11
Monday, 22 Aug 2016 

Biocryst Pharmaceuticals Inc :D. E. Shaw & Co., L.P. reports a passive stake of 5.1 percent in Biocryst Pharmaceuticals Inc as of August 11, 2016 - Sec filing.  Full Article

Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals
Wednesday, 17 Aug 2016 

Biocryst Pharmaceuticals Inc : Baker Brosadvisors LP'S Felix Baker reports a passive stake of 14.99 pct in Biocryst Pharmaceuticals Inc - SEC filing .Baker Bros' Felix Baker's stake of about 11.1 million shares in Biocryst Pharmaceuticals includes 75,000 shares of co's common stock underlying options.  Full Article

Felix Baker reports stake of 14.99 pct in BioCryst Pharmaceuticals
Tuesday, 16 Aug 2016 

BioCryst Pharmaceuticals Inc : Felix J. Baker reports a stake of 14.99% in BioCryst Pharmaceuticals Inc as of Aug 12 - SEC filing .Felix J. Baker reported a stake of 20.5% in BioCryst Pharmaceuticals Inc as of Feb 4 - SEC filing.  Full Article

Deerfield Mgmt Reports 6.64 pct passive stake in BioCryst Pharmaceuticals
Friday, 12 Aug 2016 

Biocryst Pharmaceuticals Inc :Deerfield Mgmt, L.P. Reports 6.64 pct passive stake in BioCryst Pharmaceuticals as of August 12, 2016 - SEC Filing.  Full Article

Biocryst Q2 loss per share $0.22
Thursday, 4 Aug 2016 

BioCryst Pharmaceuticals Inc : BioCryst reports second quarter 2016 financial results . Q2 revenue $4.8 million versus I/B/E/S view $3.9 million . Q2 loss per share $0.22 . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Expects 2016 net operating cash use to be in range of $55 to $75 million . Says expect initial data from apex-1 to be available by year end 2016 .Expects 2016 operating expenses to be in range of $78 to $98 million.  Full Article

BRIEF-BioCryst Pharma files for mixed shelf of up to $200 million‍​

* Files for mixed shelf of up to $200 million - SEC filing‍​ Source text: (http://bit.ly/2m4wZHE) Further company coverage: